BCART.BR - Biocartis Group NV

Brussels - Brussels Delayed Price. Currency in EUR
10.76
+0.10 (+0.94%)
At close: 5:35PM CEST
Stock chart is not supported by your current browser
Previous Close10.66
Open10.70
Bid0.00 x 0
Ask0.00 x 0
Day's Range10.60 - 10.84
52 Week Range9.67 - 12.80
Volume34,980
Avg. Volume102,980
Market Cap606.671M
Beta (3Y Monthly)1.73
PE Ratio (TTM)N/A
EPS (TTM)-0.94
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est17.02
  • GlobeNewswire2 months ago

    Biocartis Group NV: Biocartis and Kite Sign Agreement for Development of Assays supporting Kite's Therapies

    Biocartis Group NV (the `Company` or `Biocartis`), an innovative molecular diagnostics company (Euronext Brussels: BCART), today announced that it has entered into a Master Development and Commercialization Agreement with Kite, a Gilead Company (a pharmaceutical company engaged in the development of innovative cancer cell therapies). The agreement is aimed at the development of molecular-based assays on Biocartis` molecular diagnostics Idylla(TM) platform that are supportive to Kite`s therapies.

  • GlobeNewswire2 months ago

    Biocartis Group NV: Disclosure of transparency notifications

    Biocartis Group NV (the `Company` or `Biocartis`), an innovative molecular diagnostics company (Euronext Brussels: BCART), announces today, in accordance with Article 14, paragraph 1 of the Belgian Act of 2 May 2007 on the disclosure of major shareholdings in issuers whose shares are admitted to trading on a regulated market (the `Belgian Transparency Act`), that it received transparency notifications from both OppenheimerFunds, Inc. (`OFI`) and Invesco Ltd. (`Invesco`) following Invesco`s acquisition of OFI. The transparency notification by OFI received on 25 May 2019 (`OppenheimerFunds Notification`), indicated that on 24 May 2019, OFI no longer has voting rights over Biocartis` securities, and the transparency notification by Invesco received on 28 May 2019 (`Invesco Notification`), indicated that on 24 May 2019, Invesco increased above the 10% notification threshold, now holding 12.36% of the voting rights in Biocartis.

  • GlobeNewswire2 months ago

    Biocartis Group NV: Disclosure of a transparency notification

    Biocartis Group NV (the `Company` or `Biocartis`), an innovative molecular diagnostics company (Euronext Brussels: BCART), announces today, in accordance with Article 14, paragraph 1 of the Belgian Act of 2 May 2007 on the disclosure of major shareholdings in issuers whose shares are admitted to trading on a regulated market (the `Belgian Transparency Act`), that it received a transparency notification on 15 May 2019 (the `Notification`), indicating that on 13 May 2019 the participation of OppenheimerFunds, Inc. increased above the 10% notification threshold. OppenheimerFunds, Inc. now holds 10.02% of the voting rights in Biocartis.

  • GlobeNewswire2 months ago

    Biocartis Group NV: Idylla(TM) MSI Performance Study Selected for Publication at ASCO Conference

    PRESS RELEASE : 16 May 2019, 07:00 CEST   Idylla(TM) MSI Performance Study Selected for Publication at ASCO Conference Mechelen, Belgium, 16 May 2019 - Biocartis Group NV (the `Company` or `Biocartis`), ...

  • GlobeNewswire2 months ago

    Biocartis Group NV: Results of the annual shareholders' meeting held on 10 May 2019

    Biocartis Group NV (the `Company` or `Biocartis`), an innovative molecular diagnostics company (Euronext Brussels: BCART), held its annual shareholders` meeting in Mechelen today. The shareholders approved all items on the agenda. All documents relating to the annual shareholders` meeting can be consulted on the website of the Company.

  • GlobeNewswire2 months ago

    Biocartis Group NV: BIOCARTIS ANNOUNCES FINAL TERMS OF ITS EUR 150 MILLION SENIOR UNSECURED CONVERTIBLE BONDS DUE 9 MAY 2024

    Following the two press releases issued on 2 May 2019, Biocartis Group NV ("Biocartis" or the "Company"), an innovative molecular diagnostics company (Euronext Brussels: BCART), announces the final pricing of the offering (the "Offering") of EUR 150 million senior unsecured convertible bonds due 9 May 2024 (the "Bonds"). The initial price for the conversion of the Bonds into shares of the Company shall be EUR 12.8913, representing a 25% premium above the reference price of EUR 10.3130, being the volume weighted average price (VWAP) of Biocartis` ordinary shares on the regulated market of Euronext Brussels on 2 May 2019. An application will be made for the Bonds to be listed and admitted to trading on the regulated market of Euronext Brussels by no later than 1 December 2019.

  • GlobeNewswire2 months ago

    Biocartis Group NV: BIOCARTIS ANNOUNCES SUCCESSFUL PLACEMENT OF EUR 150 MILLION SENIOR UNSECURED CONVERTIBLE BONDS DUE 9 MAY 2024

    With reference to the press release issued on 2 May 2019 at 08:00 CEST, Biocartis Group NV ("Biocartis" or the "Company"), an innovative molecular diagnostics company (Euronext Brussels: BCART), announces that the offering (the "Offering") of EUR 150 million senior unsecured convertible bonds due 9 May 2024 (the "Bonds") has been successfully completed. This convertible bonds issue allows us to diversify our capital structure with a new financing instrument that enables us to lower our overall cost of capital and to attract interest from a new pool of investors. Driven by a strong momentum in the marketing of the transaction, we managed to attract interest from a renowned group of international and local institutional investors.

  • GlobeNewswire2 months ago

    Biocartis Group NV: BIOCARTIS LAUNCHES CONVERTIBLE BONDS OFFERING OF EUR 125 MILLION

    Mechelen, Belgium, 2 May 2019 - Biocartis Group NV ("Biocartis" or the "Company"), an innovative molecular diagnostics company (Euronext Brussels: BCART), announces today the launch of an offering (the "Offering") of senior unsecured convertible bonds due 9 May 2024 (the "Bonds"), for an initial aggregate principal amount of EUR 125 million with an increase option of up to EUR 25 million. The Company currently envisages using the net proceeds to fund its growth, in particular to support and expand the development and commercialization of the Idylla(TM) test menu and applications, its sales and marketing activities, further investments in its cartridge manufacturing capacity, and for working capital. The Offering will enable the Company to diversify its sources of financing and pro-actively optimize its capital structure.

  • GlobeNewswire3 months ago

    Biocartis Group NV: BIOCARTIS Q1 2019 BUSINESS UPDATE

    PRESS RELEASE : REGULATED INFORMATION Thursday 25 April 2019, 07:00 CEST BIOCARTIS Q1 2019 BUSINESS UPDATE Mechelen, Belgium , 25 April 2019 - Biocartis Group NV (the `Company` or `Biocartis`), an innovative ...

  • GlobeNewswire3 months ago

    Biocartis Group NV: Biocartis Announces Global Collaboration with Covance

    Biocartis Group NV (the `Company` or `Biocartis`), an innovative molecular diagnostics company (Euronext Brussels: BCART), today announces the global strategic commercialization agreement with Covance, LabCorp`s Drug Development business. Several Idylla(TM) instruments have already been placed at Covance sites in the US and China[2] to support global oncology trials.

  • Thomson Reuters StreetEvents3 months ago

    Edited Transcript of BCART.BR earnings conference call or presentation 1-Mar-18 1:00pm GMT

    Full Year 2017 Biocartis Group NV Earnings Call

  • Thomson Reuters StreetEvents3 months ago

    Edited Transcript of BCART.BR earnings conference call or presentation 6-Sep-18 12:00pm GMT

    Half Year 2018 Biocartis Group NV Earnings Call

  • GlobeNewswire3 months ago

    Biocartis Group NV: Invitation to Annual Shareholders' Meeting

    Invitation to Annual Shareholders' Meeting Biocartis Group NV (the 'Company' or 'Biocartis'), an innovative molecular diagnostics company (Euronext Brussels: BCART), has the.

  • GlobeNewswire3 months ago

    Biocartis Group NV: DISCLOSURE OF OUTSTANDING VOTING SECURITIES

    Biocartis Group NV (the `Company` or `Biocartis`), an innovative molecular diagnostics company (Euronext Brussels: BCART), today announces that 21,000 new shares were issued on 4 April 2019 as a result of the exercise of stock options (each stock option having the form of a warrant) under the 2013 Plan.

  • GlobeNewswire3 months ago

    Biocartis Group NV: Biocartis announces publication of its 2018 annual report

    Biocartis announces publication of its 2018 annual report Mechelen, Belgium, 4 April 2019 - Biocartis Group NV (the 'Company' or 'Biocartis'), an innovative molecular.

  • GlobeNewswire4 months ago

    Biocartis Group NV: Biocartis and Bristol-Myers Squibb Sign Collaboration Agreement for MSI Testing with Immuno-Oncology Therapies

    PRESS RELEASE                                                            12 March 2019, 07:00 CET Biocartis and Bristol-Myers Squibb Sign Collaboration Agreement for MSI Testing with Immuno-Oncology Therapies ...

  • GlobeNewswire5 months ago

    Biocartis Group NV: Biocartis announces CE-IVD marking of its Idylla(TM) MSI Test

       PRESS RELEASE                                                             28 February 2019, 07:01 CET Biocartis announces CE-IVD marking of its Idylla(TM) MSI Test Mechelen, Belgium, 28 February 2019 ...

  • GlobeNewswire5 months ago

    Biocartis Group NV: BIOCARTIS ANNOUNCES 2018 RESULTS AND 2019 OUTLOOK

        PRESS RELEASE:  REGULATED INFORMATION Thursday, 28 February 2019, 07:00 CET BIOCARTIS ANNOUNCES 2018 RESULTS AND 2019 OUTLOOK Mechelen, Belgium , 28 February 2019 - Biocartis Group NV (the `Company` ...

  • GlobeNewswire5 months ago

    Biocartis Group NV: Biocartis Places Its 1,000th Idylla(TM) Instrument with Geisinger in US

    Biocartis Group NV (the `Company` or `Biocartis`), an innovative molecular diagnostics company, today announces that it has placed its 1,000th Idylla(TM) instrument. The instrument was placed in the US with Diagnostic Medicine Institute at Geisinger. The Geisinger Medical Center in Danville, Pennsylvania (US) is one of the main hospitals in the Geisinger group which covers 13 hospital campuses, two research centers and close to 30 specialties, including an advanced cancer institute in the Pennsylvania and New Jersey regions.

  • GlobeNewswire5 months ago

    Biocartis Group NV: BIOCARTIS TO HOST WEBCAST FOR ANNOUNCEMENT 2018 FINANCIAL RESULTS ON 28 FEBRUARY 2019

        PRESS RELEASE : REGULATED INFORMATION 21 February 2019, 07:00 CET BioCARTIS to Host Webcast FOR ANNOUNCEMENT 2018 FINANCIAL Results on 28 FEBRUARY 2019 Mechelen, Belgium, 21 February 2019 - Biocartis ...